Breast Cancer Therapeutics Market 2020: Latest Devices, Competitive Share Analysis, Growth Parameters, Company Profiles, Technology Advancements and Future Trends
Cancer is essentially uncontrolled growth of certain cells in the body that crowd out normal cells over time. When cells in the breast grow out of control it leads to breast cancer. These cells generally form a tumor that can felt as a lump, which can further be confirmed using a mammogram. The tumor is considered malignant, if the cells grow into surrounding tissues or spread to other parts of the body. Breast cancer occurs majorly in women, though in some cases men can also contract breast cancer. Mutations in DNA can result normal breast cells to become cancerous cells. Some DNA changes are hereditary and can significantly increase the risk of breast cancer. Moreover, lifestyle-related risk factors such as consumption of fast food and lack of exercise can increase chances of developing breast cancer. However, the exact cause of the disease is yet unknown.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/250
According to the Breast Cancer Organization, around 252,710 new cases of breast cancer are identified in the U.S., of which 63,410 cases were non-invasive breast cancer in 2017. Moreover, in the U.S., breast cancer death rates are higher compared to any other cancer, besides lung cancer among women. Breast cancer is especially prevalent among women under 45 years of age and African American women compared to white women.
Breast Cancer Therapeutics Market
On the basis of type of drug class, the global market is classified into:
- HER2 Inhibitors
- Mitotic Inhibitors
- Aromatase Inhibitors
- Hormone Receptor Agonist/Antagonist
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/250
Globally breast cancer is the most common cancer in women, with a prevalence of around 1.7 million in 2012, the second-most common cancer overall. This represents 12% of all new cancer cases and 25% of all cancers in women. Belgium had the highest rate of breast cancer, followed by Denmark and France, respectively. Marginally less number of cases of breast cancer were diagnosed in emerging economies. The highest occurrence of this type of cancer was in Northern America and Oceania, whereas the lowest incidence rate was in Asia Pacific and Africa.
Increasing occurrence of the disease especially in the developed countries is expected to drive growth of the breast cancer therapeutics market
According to World Health Organization statistics, breast cancer is the second-most predominant type (whereas lung cancer is first) of the disease globally, and the most common type in females. In women, this type of cancer accounts for 20% of all invasive and 13% of all female cancers, and is responsible for 15% of deaths caused by the disease globally, including females and males. Every year, around 200,000 new cases in women and approximately 2,000 new cases of breast cancer are diagnosed in men. The incidence of breast cancer remained steady in white women and increased to some extent (less than 1% year) in African American women. Epidemiologist’s estimates that the established incident cases of breast cancer in women will grow by over the following decade to reach 949,161 cases by 2025. This is expected to drive the global breast cancer therapeutics market growth over the forecast period.
Innovation of therapy with improved success rate is expected to offer lucrative growth opportunities for market players. Despite high costs involved in research and development, pharmaceutical companies are showing increased interest in this field. This is expected to drive breast cancer therapeutics market growth.
Key players operating in the global breast cancer therapeutics market include AstraZeneca plc, Eli Lilly and Company, Eisai Co., Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Pfizer, Inc., Novartis International AG, Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/breast-cancer-therapeutics-market-250
- Key players in the market are focused on adopting strategies such as research and development, in order to gain competitive edge in the global market. For instance, in July 2019, Eli Lilly and Company, a U.S.-based pharmaceutical company, announced positive results for Verzenio (abemaciclib), which demonstrated significant improvement in overall survival of Phase 3 MONARCH 2 clinical trial. Verzenio is indicated for the treatment of advanced or metastatic breast cancer.
- Key companies in the market are focused on gaining product approval from regulatory authorities, in order to expand their product portfolio and enhance their market presence. For instance, in July 2019, Eisai Co., Ltd., a Japan-based pharmaceutical company, received the new drug approval for its anticancer agent Halaven (eribulin mesylate) from China National Medical Products Administration (NMPA), which is indicated for the use people suffering from metastatic or locally advanced breast cancer.
- Key companies in the market are focused on gaining product approval from regulatory authorities, in order to expand their product portfolio and gain competitive edge in the global market. For instance, in August 2019, Roche AG received product approval for Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) from European Commission. This is indicated for the patients with metastatic or unresectable locally advanced triple negative breast cancer.
Table of Content
Global Breast Cancer Therapeutics Market Research Report
Section 1: Global Breast Cancer Therapeutics Industry Overview
Section 2: Global Economic Impact on Breast Cancer Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Breast Cancer Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Breast Cancer Therapeutics Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire